Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Despite the role of epidermal growth factor receptor (EGFR) signaling in head and neck squamous cell carcinoma (HNSCC) development and progression, clinical trials involving EGFR tyrosine kinase inhibitors (TKIs) have yielded poor results in HNSCC patients. Mechanisms of acquired resistance to the E...

Full description

Saved in:
Bibliographic Details
Main Authors: Aditya Stanam, Laurie Love-Homan, Tisha S. Joseph, Madelyn Espinosa-Cotton, Andrean L. Simons
Format: Article
Language:English
Published: Wiley 2015-08-01
Series:Molecular Oncology
Subjects:
HNSCC
EGFR
Erlotinib
Resistance
IL-6
Tocilizumab
Online Access:https://doi.org/10.1016/j.molonc.2015.03.008
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1016/j.molonc.2015.03.008

Similar Items